Related Experiment Video
Updated: Aug 17, 2026
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
Predicting chronic immune thrombocytopenia in children using IFNA17 rs9298814 polymorphism and clinical features: a
Hong Nguyen Thi Mong1, Thi Mong Ngoc Nguyen2, Quang Vinh Bui1
1School of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam.
Insights
Identifying children at risk for chronic immune thrombocytopenia (ITP) is crucial. A study found that clinical factors and the IFNA17 rs9298814 genotype can predict chronic ITP development, improving early risk stratification.
Area of Science:
- Pediatric Hematology
- Immunology
- Genetics
Background:
- Immune thrombocytopenia (ITP) is a common childhood hematologic disorder.
- Approximately 20-25% of children with ITP develop chronic disease.
- Early identification of children at risk for chronic ITP remains a clinical challenge.
Purpose of the Study:
- To identify predictors of chronic immune thrombocytopenia (ITP) in children.
- To develop and validate prediction models for chronic ITP.
- To assess the role of IFNA17 rs9298814 genotype in chronic ITP risk.
Main Methods:
- Prospective cohort study of 205 children with newly diagnosed ITP.
- Assessment of clinical, laboratory variables, and IFNA17 rs9298814 genotype.
- Multivariable analysis and development of clinical and integrated prediction models.
Main Results:
- 48 (23.4%) children developed chronic ITP over 12 months.
- Predictors of chronic ITP included older age at onset, longer bleeding duration, lower platelet count at 4 weeks, and IFNA17 rs9298814 TT genotype.
- An IFNA17-integrated model showed improved predictive accuracy (AUC 0.95) compared to a clinical model (AUC 0.92).
Conclusions:
- Clinical factors and IFNA17 rs9298814 genotype are significant contributors to chronic ITP risk in children.
- Integrating IFNA17 genotype into prediction models enhances early risk stratification for chronic ITP.
- Further external validation of the developed models is warranted.
Abstract:
Immune thrombocytopenia (ITP) is a common acquired hematologic disorder in childhood, with approximately 20-25% of children progressing to chronic disease. Early identification of those at risk remains a major clinical challenge. In this prospective cohort study, 205 children with newly diagnosed ITP at a tertiary center in Vietnam were followed for 12 months. Clinical and laboratory variables, along with IFNA17 rs9298814 genotype, were assessed. Multivariable analysis identified independent predictors of chronic ITP, defined as platelet counts <100 × 109/L persisting beyond 12 months. Of the 205 children, 48 (23.4%) developed chronic ITP. Older age at onset, a longer bleeding-onset duration, and a lower platelet count at 4 weeks were associated with chronic ITP, as was the IFNA17 rs9298814 TT genotype (homozygosity for the reference allele; i.e. absence of the G variant); conversely, carriage of the minor G allele was protective (G-allele odds ratio [OR] 0.10, 95% confidence interval [CI] 0.05-0.20; TT versus G-carrier OR 26.4, 95% CI 11.1-63.1). Two prediction models were developed and expressed as a risk score: a clinical model (age at onset, bleeding-onset duration, platelet count at 4 weeks, and antinuclear antibody status) with an area under the receiver operating characteristic curve (AUC) of 0.92 (95% CI 0.88-0.96), and an IFNA17-integrated model with a significantly improved AUC of 0.95 (95% CI 0.92-0.98; DeLong test p = 0.005). The integrated model demonstrated good calibration. A nomogram and bedside score were constructed for clinical application. Both clinical factors and host genetic variation contribute to the risk of chronic ITP in children. Integrating IFNA17 rs9298814 genotype into clinical prediction models improves early risk stratification. External validation in independent cohorts is warranted.
